- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.01. | AccuStem Sciences, Inc.: AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP) | 293 | GlobeNewswire (Europe) | Initial study will enable further collaboration on the predictive capabilities of StemPrintERPHOENIX, Jan. 08, 2026), a clinical stage diagnostics company dedicated to improving outcomes for patients... ► Artikel lesen | |
| 26.11.25 | Accustem Sciences Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.11.25 | Accustem Sciences Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.09.25 | AccuStem Sciences, Inc.: AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning | 452 | GlobeNewswire (Europe) | PHOENIX, Ariz. and LONDON, Sept. 17, 2025), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced an expansion of its blood-based... ► Artikel lesen | |
| 16.09.25 | AccuStem Sciences, Inc.: AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th | 300 | GlobeNewswire (Europe) | Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.comPHOENIX and LONDON, Sept. 16, 2025), a clinical stage diagnostics... ► Artikel lesen | |
| 16.06.25 | AccuStem Sciences, Inc. Announces Chairman Purchase of Shares | 282 | GlobeNewswire (Europe) | LONDON and PHOENIX, June 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced... ► Artikel lesen | |
| 13.06.25 | AccuStem Sciences, Inc. Announces Chairman Purchase of Shares | 283 | GlobeNewswire (Europe) | LONDON, June 13, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman... ► Artikel lesen | |
| 28.04.25 | AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening | 434 | GlobeNewswire (Europe) | LONDON and PHOENIX, Ariz., April 28, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk... ► Artikel lesen | |
| ACCUSTEM SCIENCES Aktie jetzt für 0€ handeln | |||||
| 21.04.25 | AccuStem Sciences, Inc. Announces Chairman Purchase of Shares | 298 | GlobeNewswire (Europe) | LONDON and PHOENIX, Ariz., April 21, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced... ► Artikel lesen | |
| 16.04.25 | AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan | 371 | GlobeNewswire (Europe) | LONDON and PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer... ► Artikel lesen | |
| 10.04.25 | AccuStem Sciences, Inc. Announces Chairman Purchase of Shares | 327 | GlobeNewswire (Europe) | LONDON and PHOENIX, April 10, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced... ► Artikel lesen | |
| 04.04.25 | AccuStem Sciences, Inc.: AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States | 453 | GlobeNewswire (Europe) | LONDON and PHOENIX, April 04, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,45 | -0,13 % | Jetzt zuschlagen! Mit BioNTech, Vidac Pharma und Pfizer in die Krebsforschung investieren und Renditen sichern | Die globalen Gesundheitsausgaben explodieren und der Onkologie Sektor verspricht überdurchschnittliche Renditen. Während aufgrund einer immer älter werdenden Bevölkerung die Zahl der Krebsneuerkrankungen... ► Artikel lesen | |
| MEDIGENE | 0,028 | -16,07 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 34,735 | -0,59 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MODERNA | 45,870 | -0,95 % | Moderna Stock is Soaring. Is It Too Late to Buy? | ||
| VALNEVA | 2,810 | -0,71 % | K+S Aktie: Kaufpanik - Deutsche Telekom, Hamborner, Nel ASA, TUI und Valneva - Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| EPIGENOMICS | 1,130 | -27,10 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Epigenomics AG: Vorläufiges Jahresergebnis zum... ► Artikel lesen | |
| NOVAVAX | 7,964 | -1,47 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 40,600 | -0,49 % | AtaiBeckley added to S&P Total Market, CRSP benchmark indices | ||
| REGENERON PHARMACEUTICALS | 649,00 | +0,06 % | EQS-News: Formycon AG: Formycon sichert Vermarktungsstart für Aflibercept-2mg-Biosimilar FYB203 in Europa und weiteren Territorien durch Settlement mit Regeneron und Bayer | EQS-News: Formycon AG
/ Schlagwort(e): Sonstiges
Formycon sichert Vermarktungsstart für Aflibercept-2mg-Biosimilar FYB203 in Europa und weiteren Territorien durch Settlement mit... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,190 | -2,65 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| DEFENCE THERAPEUTICS | 0,374 | +1,91 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Warrant Terms Amendment | Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| EDITAS MEDICINE | 2,040 | +1,44 % | Editas Medicine, Inc.: Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates | Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company's first-in-human clinical... ► Artikel lesen | |
| GENMAB | 222,00 | -1,60 % | Passing of Genmab A/S' Annual General Meeting | Company Announcement At Genmab A/S' Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approvedDischarge was given to the Board of Directors and the Executive Management... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,176 | +0,25 % | RBC Capital bestätigt BioCryst-Rating angesichts von Übernahmepotenzial |
Das Unternehmen ACCUSTEM SCIENCES INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACCUSTEM SCIENCES INC finden Sie auf Wallstreet Online.